To further examine whether CDC7 inhibition could sensitize resistant melanoma cells to Vemurafenib, a pharmacologic selective CDC7 inhibitor, TAK-931, was used to manipulate the kinase activity. This evidence concerns the gene CDC7 and melanoma.